July 30th, 2013
More Bad News for Valsartan
Larry Husten, PHD
In the last few days, more bad news about valsartan (Diovan, Novartis) has emerged. Another major study conducted in Japan — the Jikei Heart Study — will be retracted, and Japanese health authorities said they were investigating severe skin reactions associated with use of the drug. The new events are only the latest problems for the drug […]
NEJM Journal Watch — Recent Cardiology Articles- Strategies and Criteria for the Diagnosis and Management of Myocarditis
- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?
- Can Genetic and Social Risk Scores Improve Cardiac Risk Prediction?
- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?